Skip to content
thestock.space

On 6 Nov 2026, Glenmark Pharmaceuticals was priced at ₹2,590.00, or 50.4× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 13% and 66% a year over 3 years, with ROCE of 16% and ROE of 14%. Debt is 0.13× equity, and its dividend yield is 0.2%. It is a mid-cap company with a market cap of ₹73,096 Cr, ranked 11th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 35% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹2,365.50
Day high
₹2,682.50
Day low
₹2,365.50
Prev. close
₹2,481.80
Volume
50.4 L

Health check

3 good · 1 fair · 2 to check
  • ReturnsAhead

    +34.5% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 50.4 vs industry 28.7.

  • GrowthStrong

    Sales +13.5%, profit +66.1% a year over 3 years.

  • ProfitabilityAverage

    ROCE 16.2% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.13× equity, interest covered 10.5×, Piotroski 9 of 9.

  • Red flags3 to check

    Quarterly profit down 56.8% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹73,096 Cr, #11 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹15,838 Cr · profit ₹1,451 Cr
Market cap
₹73,096 Cr
Mid cap
P/E
50.4
Industry 28.7
Price to book
6.52
Peers 4.99
Dividend yield
0.19%
ROE
14.0%
Peers 14.7%
ROCE
16.2%
Peers 17.9%
Debt to equity
0.13
Debt ₹1,407 Cr
EPS (TTM)
₹51.41
Face value ₹1
OPM (TTM)
18.0%
Net margin 9.2%
Sales growth
−30.8%
Latest quarter vs a year ago
Profit growth
−56.8%
Latest quarter vs a year ago
Price to sales
4.62
EV/EBITDA 24.0

Strengths and risks

Risks to check

  • Quarterly profit down 56.8% on a year ago.
  • Quarterly sales down 30.8% on a year ago.
  • P/E of 50.4 against an industry P/E of 28.7.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex…

Headquarters
Mumbai
Employees
16,946
Sector
Healthcare
ISIN
INE935A01035
Website
glenmarkpharma.com

Price range

52 weeks

₹1,807.00₹2,682.50

Today

₹2,365.50₹2,682.50
Avg volume (3M)
6.5 L
1-year return
plus 34.5%
From 52-week high
minus 3.4%

Analyst consensus

11 analysts
No consensusMean target ₹2,512.82 minus 3.0%

The mean target is below today’s price.

Target range, with today’s price

Low ₹2,100.00High ₹2,750.00

Next results expected around 29 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
GLENMARKGlenmark Pharmaceuticals2,590.00plus 4.36%73,09650.46.5216.2%14.0%18.0%13.5%66.1%0.19%plus 34.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
6,0043,8883,7603,9324,157
4,8293,0183,1823,1273,575
1,175870578805582
19.6%22.4%15.4%20.5%14.0%
1,38544.537365.8284
66.541.442.65463.8
141154148173180
−1,385−184−373–−284
967534388643338
36.9%24.5%22.3%25.0%22.0%
610403301483264
21.6214.2810.6817.119.34

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+13.5%
Profit CAGR 3Y
+66.1%
EPS CAGR 3Y
+66.1%
ROE
14.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
11,43211,63513,14616,711
–+1.8%+13.0%+27.1%
10,23210,37410,79113,944
1,2001,2622,3542,767
10.5%10.8%17.9%16.6%
7738381142,290
349516207209
611631486573
−773−917−376−2,290
24036.51,3991,985
137.3%5116.7%25.2%31.4%
297−1,5021,0471,362
–minus 605.2%–+30.1%
10.53-53.2237.1148.24

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
28.228.228.228.2
9,4467,8208,82110,484
4,6081,2312,473594
5,2905,2804,7278,802
19,37214,35916,05019,908
4,2213,5683,8884,344
1,092450568454
47.379660.543.1
1,1731,6701,6911,201
12,8377,8759,84113,866
19,37214,35916,05019,908

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
625−265−8283,445
−5284,5612.1−1,283
−77.5−3,906787−2,709
19.4389−38.5−547
−608−898−751−1,358
17.6−1,164−1,5782,087
−137−118−70.4−141

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 27.2% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you